Ranbaxy backs away from Europe

Pricing pressures in Europe are prompting Ranbaxy Laboratories to ease back its operations there; revenues in the region declined 14 percent year-over-year during the first quarter. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.